UNSPSC 51263705: Tilisolol hydrochloride

This classification denotes a beta-adrenergic blocking agent C17H24N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JW02T8UTIN, chemically known as tilisolol hydrochloride, (+/-)-, but more generally known as tilisolol hydrochloride, which bears US NIH Compound Identifier 44155. European Medicines Agency schedules Tilisolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04871MIG.

Most nations, for tariff and trade purposes, schedule tilisolol hydrochloride under HS 29337900 and SITC 51561. As of Q4 2014, TILISOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)(C)NCC(COC1CN(C(=O)C2C1CCCC2)C)O.CL.

UNSPSC 51263705 Tilisolol hydrochloride is a Commodity code designated for a specific pharmaceutical active ingredient, but recent state and local procurement activity under this code shows a mismatch between the nominal scope and what is actually being solicited. The Seminole County, Florida IFB60459723LAS opportunity, posted June 30, 2026, targets naloxone and drug deactivation systems — emergency opioid-reversal products and harm-reduction equipment — not tilisolol hydrochloride. The Texas Health and Human Services Commission RFI HHS0017013, posted April 3, 2026, addresses direct-to-manufacturer prescription fulfillment infrastructure and pharmacy benefit program design rather than procurement of a specific chemical compound. Both opportunities reflect state and local demand for pharmacy-adjacent services and consumables, but neither targets the particular pharmaceutical ingredient named in the code. The issuing bodies represent a state health agency (Texas HHS) and a county government (Seminole County), reflecting health and human services procurement leadership at regional and statewide levels.

Activity under this code appears concentrated in Florida and Texas, based on the two opportunities in the recent record. The Seminole County solicitation is a traditional competitive IFB with a due date of July 26, 2023 — notably in the past relative to the posting date — requiring electronic bid submission through the county's e-Procurement Portal and including a three-month probationary period and potential FEMA funding compliance. The Texas HHS RFI, with a response deadline of April 3, 2026, represents preliminary market intelligence gathering rather than a binding competitive solicitation and signals the state's intent to develop future formal procurement specifications for pharmacy benefit programs. The code shows little relevant recent activity aligned with tilisolol hydrochloride itself; opportunities tagged to this code appear to reflect miscoding or state procurement taxonomy variation rather than active demand for this specific pharmaceutical compound.